RxDoctor Payments Data

Jessica Logel

Psychiatric/Mental Health · Norwalk, CTNPI 1417615667

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.2% of the total across 122 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) at 40.1% of the total. 2025 is the largest year on record at $3,275, 7.0 times the $466 reported in 2022. Among psychiatric/mental health clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$6,309in general payments, 2019–2025

Across 122 payments — averaging $51.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$3K
  • Teva Pharmaceuticals USA, Inc.$2K
  • Neurocrine Biosciences, Inc.$545
  • Johnson & Johnson$356
  • Otsuka America Pharmaceutical, Inc.$250
  • AbbVie$249
  • plus $687 from 4 others

What the payments were for

  • Food & beverage$6,06796%
  • Education$2424%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,309 in reported general payments places this provider in the 90th percentile of 679 psychiatric/mental health providers in Connecticut.

See all psychiatric/mental health providers in Connecticut

Medicare billing

Part B allowed, 2024
$12,756
Medicare patients
42
Services billed
141

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Aripiprazole35$4,717
Quetiapine Fumarate48$3,900
Duloxetine Hcl31$1,910
Gabapentin33$856
Mirtazapine36$718
Hydroxyzine Hcl16$650
Olanzapine31$411
Bupropion XlBupropion Hcl14$384
Venlafaxine Hcl ErVenlafaxine Hcl38$383
Clonazepam20$297
Risperidone23$275
Methylphenidate Hcl11$250
Paroxetine Hcl15$235
Lamotrigine13$223
Trazodone Hcl37$187

Paid to pharmacies, not to this prescriber.

Other psychiatric/mental health in Norwalk

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →